

Appendix 5: Demographics and Index CAM details

| Study details | | Case details | | | | | |
|-------------------------------------|---------------|--------------|-------------|---------------|---|-------------------------------|--------------------------------------|
| Author | Country | Sex | Age (years) | Diagnosis | Index clozapine starting dose; up-titration schedule | Dose at time of CAM diagnosis | Time to developing index CAM episode |
| Published cases – successful | | | | | | | |
| 1. Boscutti et al. 2022 | Italy | Male | 31 | TRS | 25 mg; Increased incrementally reaching 50mg by 2 days, 100mg by 6 days, 200mg by 8 days. | 300mg | 19 days |
| 2. Bouhlef 2 et al. 2014 | Tunisia | Male | 30 | TRS | 25mg; Increased to 300mg by 20 days. | 300mg | Unclear |
| 3. Bowers et al. 2022 | United States | Male | 23 | TRS | 10mg; Increased incrementally reaching 25mg by 2 days, 50mg by 5 days, 100mg by 7 days, 125mg by 11 days. | 125mg | 16 days |
| 4. Bray & Reid 2011 | Australia | Male | 43 | Schizophrenia | N/R | N/R | 15 days |
| 5. Carswell et al. 2013 (A) | Australia | Male | 19 | N/R | 12.5mg; As per local protocol (South Australia, Australia). | 225mg | 18 days |
| 6. Carswell et al. 2013 (B) | Australia | Female | 37 | N/R | Titration was more rapid than local protocol (South Australia, Australia), reaching 250mg by 15 days. | 250mg | 20 days |
| 7. Chow et al. 2014 | Australia | Male | 15 | TRS | As per local protocol (New South Wales, Australia). | N/R | 14 days |
| 8. Danilewitz et al. 2021 | Canada | Male | 27 | TRS | 25mg; Increased incrementally reaching 50mg by 7 days, 100mg by 11 days. | 100mg | 16 days |
| 9. Granja-Ingram et al. 2013 | United States | Male | 22 | Schizophrenia | 50mg | N/R | >30 days |

| | | | | | | | | |
|-----------------------------|----------------|--------|-----------|--------------------------|--|----------|---------|-------------------------|
| 10. Griffin et al. 2021 (A) | United States | Male | 33 | TRS | 25mg; Increased incrementally reaching 50mg by 4 days, 100mg by 11 days, 200mg by 18 days. | 150mg | 18 days | |
| 11. Griffin et al. 2021 (B) | United States | Male | 30 | TRS | N/R | 350mg | 4 years | |
| 12. Halawa et al. 2023 | Canada | Female | 18 | TRS | Increase of 25-50mg every 1-2 days reaching 300mg by 18 days. | 1) 300mg | 2) 50mg | 1) 18 days 2) 6 days |
| 13. Hassan et al. 2011 | Australia | Male | early 30s | TRS | N/R | 225mg | 19 days | |
| 14. Holden & Begum 2022 | United Kingdom | Female | 60s | Schizoaffective disorder | 12.5mg; As per local protocol (National Health Service, UK), reaching 25mg by 2 days, 50mg by 4 days, 100mg by 6 days, 150mg by 8 days. | 100mg | 18 days | |
| 15. Hosseini et al. 2020 | United States | Male | 22 | TRS | As per local guidelines (California, USA), reaching 300mg by 13 days. | 300mg | 16 days | |
| 16. Ittasakul et al. 2016 | United States | Male | 20 | Schizophrenia | Increased rapidly reaching 450mg by 11 days. | 450mg | 12 days | |
| 17. Koparal et al. 2019 | Turkey | Male | 30 | TRS | 25mg; Increased to 350mg by 16 days. | 350mg | 16 days | |
| 18. Nguyen et al. 2017 | Australia | Male | 18 | TRS | N/R | 225mg | 15 days | |
| 19. Otsuka et al. 2019 | Japan | Male | late 20s | Schizophrenia | 12.5mg; Increased incrementally reaching 25mg by 5 days, 50mg by 8 days, 100mg by 16 days. | 50mg | 18 days | |
| 20. Reid et al. 2001 | Australia | Male | 23 | TRS | 12.5mg; Increased slowly to 200mg by 14 days. | 200mg | 42 days | |
| 21. Reinders et al. 2004 | Australia | N/R | N/R | N/R | N/R | N/R | N/R | |

| | | | | | | | |
|---------------------------------------|--------------------|--------|-----|--------------------------|---|-------|---------|
| 22. Ronaldson et al. 2012 A | Australia | N/R | N/R | N/R | N/R | N/R | N/R |
| 23. Ronaldson et al. 2012 B | Australia | N/R | N/R | N/R | N/R | N/R | N/R |
| 24. Ronaldson et al. 2012 C | Australia | N/R | N/R | N/R | N/R | N/R | N/R |
| 25. Ronaldson et al. 2012 D | Australia | N/R | N/R | N/R | N/R | N/R | N/R |
| 26. Rosenfeld et al. 2010 | United States | Male | 35 | Schizoaffective disorder | Increased to 200mg by 21 days. | 200mg | 21 days |
| 27. Sarathy & Alexopoulos 2017 | Australia | Male | 29 | TRS | As per local protocol (New South Wales, Australia) | N/R | 16 days |
| 28. Shivakumar et al. 2020 | Australia / Canada | Female | 34 | Schizophrenia | Increased to 250mg by 15 days. | 250mg | 17 days |
| Published cases – Unsuccessful | | | | | | | |
| 29. Higgins et al. 2019 (A) | Canada | N/R | N/R | N/R | N/R | N/R | N/R |
| 30. Higgins et al. 2019 (B) | Canada | N/R | N/R | N/R | N/R | N/R | N/R |
| 31. Jayathilake & Singh 2009 | Australia | Male | 42 | Schizophrenia | Increased to 175mg by 10 days. | 175mg | 15 days |
| 32. Masopust et al. 2009 | Czech Republic | Male | 43 | Schizoaffective Disorder | Increased slowly to 350mg. | 350mg | 12 days |
| 33. Mudra et al. 2018 | Germany | Male | 15 | Schizophrenia | 12.5mg; Increased to 125mg by 18 days. | 125mg | 21 days |
| 34. Noel et al. 2019 (A) | Canada | Male | 26 | TRS | 12.5mg; Increased incrementally reaching 25mg by 3 days, 50mg by 10 days, 75mg by 13 days. | 75mg | 21 days |
| 35. Noel et al. 2019 (B) | Canada | Male | 25 | Schizoaffective disorder | 12.5mg; As per local protocol, reaching 25mg by 2 days, 50mg by 3 days, 100mg by 5 days, 125mg by 9 days. | 200mg | 15 days |
| 36. Noel et al. 2019 (C) | Canada | Male | 20 | Schizoaffective disorder | 12.5mg; | 200mg | 14 days |

| | | | | | | | |
|--|-----------|------|-----|--------------------------|--|---------|----------|
| | | | | | As per local protocol, reaching 25mg by 2 days, 50mg by 3 days, 100mg by 5 days, 150mg by 10 days, 200mg by 12 days. | | |
| 37. Ronaldson et al. 2012 (E) | Australia | N/R | N/R | N/R | N/R | N/R | N/R |
| 38. Ronaldson et al. 2012 (F) | Australia | N/R | N/R | N/R | N/R | N/R | N/R |
| 39. Ronaldson et al. 2012 (G) | Australia | N/R | N/R | N/R | N/R | N/R | N/R |
| 40. Ronaldson et al. 2012 (H) | Australia | N/R | N/R | N/R | N/R | N/R | N/R |
| 41. Smith et al. 2014 | Australia | Male | 45 | Schizophrenia | 'Fast' dose escalation following self-cessation after previous clozapine treatment for 10 years. | 400mg | 22 days |
| 42. Thanasan 2010 | Malaysia | Male | 37 | Schizophrenia | N/R | 700mg | 12 years |
| Unpublished case Reports – successful | | | | | | | |
| 43. McMahon et al. 2023 – CD (A) | Australia | Male | 33 | TRS | As per local protocol (Queensland, Australia), reaching 100mg by 7 days, 200mg by 14 days. | 200mg | 18 days |
| 44. McMahon et al. 2023 – BA (B) | Australia | Male | 36 | TRS | As per local protocol (Queensland, Australia), reaching 200mg by 17 days. | 200mg | 20 days |
| 45. Qubad et al. 2023 | Germany | Male | 27 | Schizoaffective disorder | 12.5mg; Increases of 12.5mg per day, reaching 200mg by 16 days. | Unclear | 19 days |

N/R – Not reported; TRS – treatment resistant schizophrenia; CAM – clozapine associated myocarditis